Prenatal serotonin reuptake inhibitor exposure is common and neonatal outcomes vary greatly, often leading to confusion about whether to use or even continue antenatal use of these antidepressants. Importantly, some but not all infants are affected, which raises questions about how maternal drug metabolism contributes to fetal drug exposure. To address this key question, our paper reviews the role of key maternal, fetal, and placental pharmacokinetic, metabolic, and genetic factors that affect the extent of fetal drug exposure. Considering the role of these factors may further our understanding of variables that may assist in optimizing maternal psychopharmacotherapy during pregnancy and neonatal outcomes.
Vesga-LopezOBlancoCKeyesK, Psychiatric disorders in pregnant and postpartum women in the United States. Arch Gen Psychiatry. 2008;65(7):805–815.
2.
OberlanderTFWarburtonWMisriS, Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry. 2006;63(8):898–906.
3.
BennettHAEinarsonATaddioA, Prevalence of depression during pregnancy: Systematic review. Obstet Gynecol. 2004;103(4):698–709.
4.
WarburtonWHertzmanCOberlanderTF. A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health. Acta Psychiatr Scand. 2010;121(6):471–479.
5.
Moses-KolkoELBogenDPerelJ, Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: Literature review and implications for clinical applications. JAMA. 2005;293(19):2372–2383.
6.
CohenLSAltshulerLLHarlowBL, Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 2006;295(5):499–507.
7.
YonkersKAWisnerKLStewartDE, The management of depression during pregnancy: A report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry. 2009;31(5):403–413.
8.
CooperWOWillyMEPontSJ, Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol. 2007; 196(6): 544–545.
9.
KallenBOlaussonPO. Maternal use of selective serotonin reuptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf. 2008;17(8):801–806.
10.
AlwanSReefhuisJRasmussenSA, Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med. 2007;356(26):2684–2692.
11.
OberlanderTFMisriSFitzgeraldCE, Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry. 2004;65(2):230–237.
12.
LaineKKytöläJBertilssonL.Severe adverse effects in a newborn with two defective CYP2D6 alleles after exposure to paroxetine during late pregnancy. Ther Drug Monit. 2004;26(6):685–687.
13.
ZeskindPSStephensLE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics. 2004;113(2):368–375.
14.
MulderEJVerversFFde HeusR, Selective serotonin reuptake inhibitors affect neurobehavioral development in the human fetus. Neuropsychopharmacology. 2011;36(10):1961–1971.
15.
RurakDLimKSandersA, Third trimester fetal heart rate and Doppler middle cerebral artery blood flow velocity characteristics during prenatal selective serotonin reuptake inhibitor exposure. Pediatr Res. 2011;70(1):96–101.
16.
OberlanderTFWeinbergJPapsdorfM, Prenatal exposure to maternal depression, neonatal methylation of human glucocorticoid receptor gene (NR3C1) and infant cortisol stress responses. Epigenetics. 2008;3(2):97–106.
17.
DavidsonSProkonovDTalerM, Effect of exposure to selective serotonin reuptake inhibitors in utero on fetal growth: Potential role for the IGF-I and HPA axes. Pediatr Res. 2009;65(2):236–241.
18.
HiemkeCHartterS.Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther. 2000;85(1):11–28.
19.
DeVaneCL. Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. Cell Mol Neurobiol. 1999;19(4):443–466.
20.
FogelmanSMSchmiderJVenkatakrishnanK, O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: Effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology. 1999;20(5):480–490.
21.
MartinezCAlbetCAgundezJA, Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3Aby H2-receptor antagonists. Clin Pharmacol Ther. 1999;65(4):369–376.
22.
KimJRiggsKWMisriS, Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding. Br J Clin Pharmacol. 2006;61(2):155–163.
23.
SimS, The Human Cytochrome P450 (CYP) Allele Nomenclature Committee. The human cytochrome P450 (CYP)allele nomenclature database [Internet], [place of publication unknown]: The Human Cytochrome P450 (CYP) Allele Nomenclature Committee; [year of publication unknown] [updated 2012 Jan 20; cited 2012 Feb 07]. Available from: http://cypalleles.ki.se.
24.
BradfordLD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002;3(2):229–243.
25.
BijlMJVisserLEHofmanA, Influence of the CYP2D64 polymorphism on dose, switching and discontinuation of antidepressants. Br J Clin Pharmacol. 2008;65(4):558–564.
26.
TsaiMHLinKMHsiaoMC, Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Pharmacogenomics. 2010;11(4):537–546.
27.
PreskornSHNicholsAIPaulJ, Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system. J Psychiatr Pract. 2008;14(6):368–378.
28.
AndersonGD. Pregnancy-induced changes in pharmacokinetics: A mechanistic-based approach. Clin Pharmacokinet. 2005;44(10):989–1008.
29.
JeongH.Altered drug metabolism during pregnancy: Hormonal regulation of drug-metabolizing enzymes. Expert Opin Drug Metab Toxicol. 2010;6(6):689–699.
30.
WadeliusMDarjEFrenneG, Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther. 1997;62(4):400–407.
31.
FreemanMPNolanPEJrDavisMF, Pharmacokinetics of sertraline across pregnancy and postpartum. J Clin Psychopharmacol. 2008;28(6):646–653.
32.
VerversFFVoorbijHAZwartsP, Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy. Clin Pharmacokinet. 2009;48(10):677–683.
33.
PreskornSHBorgesSFlockhartD.Clinically relevant pharmacology of neuropsychiatrie drugs approved over the last three years: Part I. J Psychiatr Pract. 2006;12(4):244–249.
34.
PelkonenOTurpeinenMHakkolaJ, Inhibition and induction of human cytochrome P450 enzymes: Current status. Arch Toxicol. 2008;82(10):667–715.
35.
AlfaroCLLamYWSimpsonJ, CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline. J Clin Psychopharmacol. 1999;19(2): 155–163.
36.
DeVaneCLStoweZNDonovanJL, Therapeutic drug monitoring of psychoactive drugs during pregnancy in the genomic era: Challenges and opportunities. J Psychopharmacol. 2006;20(4 Suppl):54–59.
37.
GarnettWR. Clinical implications of drug interactions with coxibs. Pharmacotherapy. 2001;21(10):1223–1232.
38.
Indiana University School of Medicine, Division of Clinical PharmacologyP450 drug interaction table: Abbreviated “clinically relevant” table [Internet]. Indianapolis (IN): The Trustees of Indiana University; 2009 [updated 2012 Mar 06; 2012 Jan 03]. Available from: http://medicine.iupui.edu/clinpharm/DDIs/clinicalTable.aspx.
39.
LiXQAnderssonTBAhlströmM, Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32(8):821–827.
40.
ZhouSFZhouZWYangLP, Substrates, inducers, inhibitors and structure-activity relationships of human cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480–3675.
41.
PascussiJMDrocourtLGerbal-ChaloinS, Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. Eur J Biochem. 2001;268(24):6346–6358.
42.
YudinMHvan SchalkwykJVan EykN, Antibiotic therapy in preterm premature rupture of the membranes. J Obstet Gynaecol Can. 2009;31(9): 863–874. English, French.
43.
MageeLAAbalosEvon DadelszenP, How to manage hypertension in pregnancy effectively. Br J Clin Pharmacol. 2011;72(3):394–401.
44.
ArranzMJde LeonJ.Pharmacogenetics and pharmacogenomics of schizophrenia: A review of last decade of research. Mol Psychiatry. 2007;12(8):707–747.
45.
NiwaTInoue-YamamotoSShiragaT, Effect of antifungal drugs on cytochrome P450 (CYP) 1A2, CYP2D6, and CYP2E1 activities in human liver microsomes. Biol Pharm Bull. 2005;28(9):1813–1816.
46.
LampeJWKingIBLiS, Brassica vegetables increase and apiaceous vegetables decrease cytochrome P450 1A2 activity in humans: Changes in caffeine metabolite ratios in response to controlled vegetable diets. Carcinogenesis. 2000;21(6):1157–1162.
47.
KailMAClausenJ.Dietary effect on mixed function P450 1A2 activity assayed by estimation of caffeine metabolism in man. Hum Exp Toxicol. 1995;14(10):801–807.
48.
FricMPfuhlmannBLauxG, The influence of smoking on the serum level of duloxetine. Pharmacopsychiatry. 2008;41(4):151–155.
49.
CarterAMEndersAC. Comparative aspects of trophoblast development and placentation. Reprod Biol Endocrinol. 2004;2:46.
50.
FaberJJThornburgKL. Placental physiology. New York (NY): Raven Press; 1983.
51.
WishartDSKnoxCGuoAC, DrugBank: A comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006;34(Database issue):D668–D672.
52.
RamponoJSimmerKIlettKF, Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry. 2009;42(3):95–100.
53.
HillMDAbramsonFP. The significance of plasma protein binding on the fetal/maternal distribution of drugs at steady-state. Clin Pharmacokinet. 1988;14(3): 156–170.
54.
SzetoHHUmansJGRubinowSI. The contribution of transplacental clearances and fetal clearance to drug disposition in the ovine maternal–fetal unit. Drug Metab Dispos. 1982;10(4):382–386.
55.
KumarSTonnGRKwanE, Estimation of transplacental and nonplacental diphenhydramine clearances in the fetal lamb: The impact of fetal first-pass hepatic drug uptake. J Pharmacol Exp Ther. 1997;282(2):617–632.
RurakDWWrightMRAxelsonJE. Drug disposition and effects in the fetus. J Dev Physiol. 1991;15(1):33–44.
58.
HinesRNMcCarverDG. The ontogeny of human drug-metabolizing enzymes: Phase I oxidative enzymes. J Pharmacol Exp Ther. 2002;300(2):355–360.
59.
McCarverDGHinesRN. The ontogeny of human drug-metabolizing enzymes: Phase II conjugation enzymes and regulatory mechanisms. J Pharmacol Exp Ther. 2002;300(2):361–366.
60.
SpinaESantoroVD'ArrigoC.Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: An update. Clin Ther. 2008;30(7): 1206–1227.
61.
RingBJEcksteinJAGillespieJS, Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine. J Pharmacol Exp Ther. 2001;297(3): 1044–1050.
ObachRSCoxLMTremaineLM. Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: An in vitro study. Drug Metab Dispos. 2005;33(2):262–270.
64.
KobayashiKChibaKYagiT, Identification of cytochrome P450 isoforms involved in Citalopram N-demethylation by human liver microsomes. J Pharmacol Exp Ther. 1997;280(2):927–933.
